Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Doxofylline is a methylxanthine derivative and bronchodilator used primarily for the treatment of chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). It is structurally related to theophylline but has a better safety profile with fewer side effects. The main mechanism of action involves inhibition of phosphodiesterase enzymes (notably PDE3 and PDE4), leading to increased cyclic AMP levels, which causes relaxation of bronchial smooth muscle and bronchodilation. Doxofylline also exhibits anti-inflammatory properties, partly by favoring interleukin-10 release through phosphodiesterase inhibition. Unlike theophylline, it does not significantly inhibit histone deacetylases or act as an antagonist at adenosine receptors except at very high concentrations. Additionally, it interacts with beta-2 adrenoceptors to induce airway smooth muscle relaxation[1][2][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on doxofylline.